GTBP - GT Biopharma begins testing of GTB-3550 February, 26 2020 08:13 AM GT Biopharma Inc. GT Biopharma (OTCQB:GTBP) says the first patient has been dosed in a Phase I/II clinical trial of its anti-CD16/IL-15/anti-CD33 TriKE, GTB-3550.More news on: GT Biopharma, Inc., Healthcare stocks news, Read more ...